Ticker brief
ALNY ALNYLAM PHARMACEUTICALS INC
Consumer, Non-cyclical · Biotechnology
last close
$224.03
1 day
-1.4%
14 days
-3.7%
mkt cap
$41.8B
signals 14d
37
authors 14d
5
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 66% rich · 100 pctile own 1y | IV/HV 1.75× |
| Skew — 25Δ RR 30d | -0.004 91 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.43 elevated | 5-session Δ +0.16 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-10-10 (z=3.7) |
| CSP screen | rank #5 · $207.5 strike · 1.06% prem | on the CSP screen (2026-10-23) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.53 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @harry03994688 | A | -0.16 | 32 | +0.60 |
| @bioinvestor24 | A | -0.87 | 2 | -0.23 |
| @Tickeron | C | +1.53 | 1 | -0.50 |
| @DanielMuvdiYT | B | -2.11 | 1 | -0.35 |
| @semodough | C | -1.06 | 1 | +0.40 |
Recent signals30of 37 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @harry03994688 | +0.45 | Expresses approval of Alnylam's culture and its continuity under the 2030 plan. | -3.4% | tweet ↗ |
| 2026-10-16 | @harry03994688 | +0.60 | Uses two large RNAi IPO financings and expanding indications to argue positively for Alnylam. | -3.4% | tweet ↗ |
| 2026-10-15 | @harry03994688 | +0.80 | Expresses high conviction in Alnylam's ongoing 2030 strategic plan and cultural continuity. | -4.3% | tweet ↗ |
| 2026-10-15 | @harry03994688 | +0.75 | Forecasts a long biotech bull market based on positioning, payer resilience, AI and a new FDA framework. | -4.3% | tweet ↗ |
| 2026-10-15 | @harry03994688 | +0.55 | Presents a bullish biotech basket thesis based on payer insulation, AI and improving clinical margins. | -4.3% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.50 | Says a new rare-disease framework is favorable for ALNY and NTLA. | -0.2% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.50 | Favors ALNY's focus on unmet, less-contested indications while noting ARWR's first drug overlaps Ionis. | -0.2% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.40 | Says cash-rich, staple and healthcare companies benefit from high rates. | -0.2% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.65 | After comparing Alzheimer's programs, explicitly says they are more bullish on ALNY. | -0.2% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.50 | Calls siRNA a large market and praises Arrowhead's technology | -0.2% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.10 | Mentions Alnylam's ALN-2232 program without a developed stance | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.70 | Presents mRNA and siRNA as transformative biotechnology platforms | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.80 | Expects Alnylam to lead ALK7 while viewing obesity as large enough for both firms | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.45 | Believes Alnylam can commercialize ALN-2232 itself, while noting uncertainty | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +1.00 | Extensive ALK7 obesity thesis concludes ALNY reaching a $1T valuation is unavoidable | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.35 | Expects Alnylam to commercialize ALN-2232 independently | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.50 | Views obesity as a lucrative market supporting self-commercialization by both firms | +0.1% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.30 | Discloses holdings in RKLB, NTLA, and ALNY while noting extreme small-cap short positioning. | +0.1% | tweet ↗ |
| 2026-10-12 | @bioinvestor24 | -0.25 | Discloses no MRNA position and says it is fully valued while comparing past biotech valuations. | -1.3% | tweet ↗ |
| 2026-10-12 | @semodough | +0.40 | Truist reiterates Buy with a $315 target and expects an in-line quarter and unchanged FY26 guidance. | -1.3% | tweet ↗ |
| 2026-10-12 | @harry03994688 | +0.70 | Long-form thesis says AI pressures conventional software and some biotech while favoring RNA/DNA drug companies. | -1.3% | tweet ↗ |
| 2026-10-11 | @harry03994688 | +0.15 | Explains that ALNY developed Leqvio and NVS commercializes it. | -3.7% | tweet ↗ |
| 2026-10-10 | @harry03994688 | +0.65 | Presents AMD, Rocket Lab, and Alnylam as long-duration growth opportunities created by temporary product setbacks. | -3.7% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.30 | Connects RNA-Puzzles expertise at Inceptive AI with its collaboration to optimize Alnylam RNAi drugs. | -3.7% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.60 | Presents AI-enabled biotech as a structural turnaround and highlights high-short-interest names benefiting from squeezes. | -3.7% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.85 | Buy ALNY heavily after its 50% correction as its R&D breadth expands. — Calls the ALNY-Inceptive collaboration and pipeline expansion a strong buying moment. | -3.7% | tweet ↗ |
| 2026-10-09 | @bioinvestor24 | -0.20 | Mocks VKTX bear cases and predicts it will surpass INSM revenue before 2030 despite waiting for next year. | -3.7% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.65 | Bullish long-term ALNY framework based on delivery, indications, manufacturing and AI R&D. | -3.7% | tweet ↗ |
| 2026-10-06 | @harry03994688 | +0.50 | Forecasts a biotech short squeeze driven by AI, improving success rates and falling long-term yields. | +0.0% | tweet ↗ |
| 2026-10-05 | @DanielMuvdiYT | -0.35 | Despite prior gains in named stocks, warns that the market is very close to a violent decline. | +1.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.